CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia

Despite worldwide promising clinical outcome of CD19 CAR-T therapy, relapse after this therapy is associated with poor prognosis and has become an urgent problem to be solved. We conducted a CD22 CAR T-cell therapy in 34 relapsed or refractory (r/r) B-ALL pediatric and adult patients who failed from...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2019-12, Vol.33 (12), p.2854-2866
Main Authors: Pan, Jing, Niu, Qing, Deng, Biping, Liu, Shuangyou, Wu, Tong, Gao, Zhiyong, Liu, Zhaoli, Zhang, Yue, Qu, Xiaomin, Zhang, Yanlei, Liu, Shaohui, Ling, Zhuojun, Lin, Yuehui, Zhao, Yongqiang, Song, Yanzhi, Tan, Xiyou, Zhang, Yan, Li, Zhihui, Yin, Zhichao, Chen, Bingzhen, Yu, Xinjian, Yan, Ju, Zheng, Qinlong, Zhou, Xuan, Gao, Jin, Chang, Alex H., Feng, Xiaoming, Tong, Chunrong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!